Events

Cyclopharm (ASX:CYC) has posted its strongest half-year performance on record, underpinned by accelerating adoption of its Technegas technology in the US, robust international sales, and fresh intellectual property milestones that extend the company’s growth runway.

Cartherics, the Melbourne-based biotechnology company developing off-the-shelf immune cell therapies for high-impact women’s diseases, has strengthened its intellectual property portfolio with the grant of a new Chinese patent.

Starpharma Holdings (ASX:SPL) has delivered a year of strategic focus and scientific progress, sharpening its efforts to extract long-term value from its proprietary dendrimer technology platform while strengthening its commercial foundations across oncology, women’s health and antiviral products.

NeuroScientific Biopharmaceuticals (ASX:NSB) has reported encouraging results from two early studies of its StemSmart mesenchymal stromal cell therapy in renal transplantation, reinforcing its potential to improve outcomes for patients facing the risks of graft rejection and transplant-related complications.

Biome Australia (ASX:BIO) has achieved a milestone result in the 2025 financial year, reporting its first full-year net profit since its founding in 2018.

Neuren Pharmaceuticals (ASX:NEU) has reported a strong first-half performance for 2025, nearly doubling its profit after tax as royalties from its Rett syndrome therapy DAYBUE (trofinetide) continue to climb and its second drug candidate NNZ-2591 advances through late-stage development.

Australian company Vaxxas has secured close to $90 million in new funding, one of the largest private biotechnology financings in the country this year, as it accelerates development of its needle-free vaccine delivery technology.

Argent BioPharma (ASX:RGT) has announced the results of an independent in vivo study evaluating the efficacy of ArtemiC, the USA OTC Unlicensed Drug Brand name of CimetrA, its lead immunomodulatory therapeutic, in a severe viral inflammatory model targeting Acute Respiratory Distress Syndrome.

Victorian researchers have achieved a world-first breakthrough in brain cancer research, showing how a new drug can suppress tumour activity in patients with low-grade gliomas.

Neuren Pharmaceuticals (ASX:NEU) has announced the initiation of the first investigational site in the US for its Phase 3 clinical trial of NNZ-2591 in Phelan-McDermid syndrome, after receiving Institutional Review Board approval.

Clinical dermatology company, Botanix Pharmaceuticals (ASX:BOT), has announced the appointment of Dr Patricia Walker to its board of directors.

Australia’s life sciences sector is growing rapidly, fuelled by pioneering science and the capital needed to take ideas from research to commercialisation.